ECONSALUT

The times for drug prescription following prioritisation have arrived. Hepatitis C drugs have paved the way for such a move.There were some ...

It is quite relevant what's going on with value based pricing by NICE. Recent documents are raising greater controversy and a blog post ...

PROJET DE LOI relatif à la santé Je regarde le communiqué de presse que la ministre française a préparé pour la présentation de la no...

Economic, Demographic, and Epidemiological Transitions and the Future of Health Labor Markets Last April a new working group for human res...

In former posts I have argued that pharmaceutical pricing is forging a new trend. The summary is in this figure (US prices): The lates...

INFORME Estudio y Propuesta de un Nuevo Marco Jurídico para el Sistema Privado de Salud If you look at health care financing in OECD count...

WSJ headlines announce a new economic slowdown. Concerns about the current state of worlwide economy and the financial sector are growing ag...

PUBLIC SERVICE MUTUALS:The Next Steps Let's start with the concept: Public Service Mutuals are organisations which: 1. have left the...

Swimming against the Current — What Might Work to Reduce Low-Value Care? While reading this NEJM article on strategies to reduce low value...

Let me ask you a question: Do you agree that your government spends 12% of the pharmaceutical budget in a new drug? I understand that if the...

Rock, Paper, Scissors: Game Theory in Everyday Life Let me pick the seven deadly social dilemmas from this book : • Prisonner Dilemma, w...

We have entered into an unknown new world: drug prices -for innovative drugs- are on track to disappear. The NHS has agreed a cap on expendi...

While I was reading the HA blog I   thought that the word innovation is like a joker, when somebody has a real concern about potential incom...

Reputation Capital: Building and Maintaining Trust in the 21st Century In the last decade there has been a proliferation of cases of fraud...